Fluzoparib is primarily used in cancer treatment, specifically as a targeted therapy for certain types of ovarian, fallopian tube, and peritoneal cancers. It functions as a PARP (poly ADP-ribose polymerase) inhibitor, which blocks enzymes involved in repairing damaged DNA in cancer cells. By inhibiting this repair mechanism, fluzoparib leads to the accumulation of DNA damage and ultimately causes cancer cell death, especially in tumors with BRCA gene mutations. It is often prescribed for patients who have received prior chemotherapy and show specific genetic vulnerabilities. Its application offers a more personalized approach in oncology, improving progression-free survival in responsive patient groups.